In This Article:
~ Joseph Dziedzic to retire as President and CEO ~
~ Payman Khales appointed President and CEO effective October 24, 2025 ~
PLANO, Texas, April 24, 2025 (GLOBE NEWSWIRE) -- Integer Holdings Corporation (NYSE: ITGR), a leading medical device contract development and manufacturing organization, today announced that Joseph Dziedzic will retire as President and Chief Executive Officer and will step down from the Board of Directors, effective October 24, 2025. At that time, Payman Khales, Chief Operating Officer, will assume the President and CEO position and join the Company’s Board. To ensure a smooth transition, Mr. Dziedzic will serve as an advisor to the Company through March 31, 2026.
“We are incredibly grateful to Joe, whose vision, strategy, and ability to create a high-performance culture has driven Integer’s significant growth and value creation during his eight-year tenure as CEO,” said Pamela G. Bailey, Chair of the Board. “Among many other accomplishments, Joe reshaped Integer’s business to focus on high growth markets that address unmet patient needs, accelerated organic and inorganic investment in differentiated technologies, and developed and implemented the Integer Production System to create consistency across our manufacturing operations. Integer is delivering on its financial objectives of above market organic sales growth with expanding margins and is well positioned to continue this growth trajectory. We wish him the very best in a well-deserved retirement.”
“It has been an honor to lead the Integer team through this pivotal period in our Company’s history, and I am proud of what we have accomplished for our customers and patients around the world,” said Mr. Dziedzic. “Payman is the natural choice to guide Integer through our next chapter of growth. He is an exceptional leader who embodies our commitment to innovation, quality and operational excellence, and his track record speaks for itself. Payman has been an integral part of the development and execution of our strategy, both within Cardio & Vascular and across the enterprise, while leading Integer’s Customer Operational Strategic Imperatives. I look forward to the Company’s continued success under Payman’s leadership.”
Mr. Khales joined Integer in 2018 as President of the Cardio & Vascular business. Under his leadership, the business established a successful market/customer-based strategy, doubling sales in seven years, accelerating market penetration, and achieving above-market growth, while improving service levels and profitability. Since becoming COO, he has overseen both of Integer’s business units, Cardio & Vascular and Cardiac Rhythm Management & Neuromodulation, along with global operations and manufacturing strategy.